5409-15-4 Usage
General Description
4-Chloro-1-hydroxy-2-naphthoic acid, also referred to as 4-chlorosalicylic acid, is an organochlorine compound often utilized in the chemical industry due to its properties. It is composed of chloro, hydroxy, and carboxy functional groups, which are attached to a naphthalene structure. Its molecular formula is C10H7ClO3, indicating ten carbon atoms, seven hydrogen atoms, one chlorine atom, and three oxygen atoms. The compound is known for its reactivity and is commonly used in reactions to form other complex organic molecules. Its potential applications and hazardous traits align with those typical of chlorinated aromatic compounds. Detailed information regarding its physical and chemical properties, including its melting point, boiling point, and density, may vary based on the specifics of its condition or form. It is crucial to handle and dispose of it properly to minimize potential threats to human health and the environment.
Check Digit Verification of cas no
The CAS Registry Mumber 5409-15-4 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 5,4,0 and 9 respectively; the second part has 2 digits, 1 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 5409-15:
(6*5)+(5*4)+(4*0)+(3*9)+(2*1)+(1*5)=84
84 % 10 = 4
So 5409-15-4 is a valid CAS Registry Number.
InChI:InChI=1/C11H7ClO3/c12-9-5-8(11(14)15)10(13)7-4-2-1-3-6(7)9/h1-5,13H,(H,14,15)
5409-15-4Relevant articles and documents
INHIBITORS OF CXCR2
-
Page/Page column 60, (2008/06/13)
The invention relates to compounds of the formula (I), in which R1, R2, X, A, B and Y1 to Y4 have the meanings indicated in the claims, and/or a pharmaceutically acceptable salt and/or a prodrug thereof. Because of their properties as inhibitors of chemokine receptors, especially as CXCR2 inhibitors, the compounds of the formula (I) and the pharmaceutically acceptable salts and prodrugs thereof are suitable for the prevention and treatment of chemokine mediated diseases.